Table 2.
Lung function abnormalities: Pooled spirometry results among studies that reported actual measurements of lung function.
| Meta-analysis | Number of study populations | Pooled estimate (95% CI) | Prediction interval | I2 |
|---|---|---|---|---|
| All TB patients | ||||
| FEV1 (L) | 24 | 2.2 (2.0–2.3) | 1.4 to 3.0 | 97.0% |
| FEV1% pred | 32 | 71.1 (66.5–75.7) | 44.3 to 97.9 | 97.2% |
| FVC (L) | 23 | 3.0 (2.8–3.1) | 2.2 to 3.7 | 95.8% |
| FVC % pred | 28 | 77.8 (73.5–82.1) | 54.3 to 101.4 | 97.1% |
| FEV1/FVC ratio | 31 | 0.76 (0.73–0.79) | 0.6 to 0.9 | 97.8% |
| Controls | ||||
| FEV1 (L) | 3 | 2.9 (2.6–3.1) | – | 92.3% |
| FEV1% pred | 2 | 89.1 (84.4–93.9) | – | 79.2% |
| FVC (L) | 2 | 3.2 (3.2–3.3) | – | 20.3% |
| FVC % pred | 2 | 83.9 (68.4–99.3) | – | 97.5% |
| FEV1/FVC ratio | 2 | 0.89 (0.76–1.02) | – | 99.5% |
| DS-TB | ||||
| FEV1 (L) | 6 | 2.2 (1.9–2.6) | 1.0 to 3.5 | 97.7% |
| FEV1% pred | 6 | 74.3 (70.6–78) | 62.3 to 86.3 | 77.2% |
| FVC (L) | 5 | 3.2 (2.9–3.5) | 2.1 to 4.2 | 92.8% |
| FVC % pred | 6 | 79.4 (72.9–85.9) | 56.0 to 102.7 | 90.8% |
| FEV1/FVC ratio | 7 | 0.77 (0.72–0.83) | 0.6 to 1.0 | 99.0% |
| MDR-TB | ||||
| FEV1 (L) | 4 | 2.1 (1.8–2.4) | 0.6 to 3.6 | 85.5% |
| FEV1% pred | 5 | 57.6 (43.2–72) | 1.4 to 100.0 | 96.9% |
| FVC (L) | 4 | 2.8 (2.6–3.1) | 1.9 to 3.8 | 61.0% |
| FVC % pred | 4 | 68.0 (51.6–84.4) | 0.0 to 100.0 | 95.0% |
| FEV1/FVC ratio | 5 | 0.71 (0.70–0.80) | 0.5 to 0.9 | 84.1% |
Pooled estimates included all persons at risk for respiratory impairment (I.e., the denominator in these estimates was all persons post-TB in the studies reporting on post-TB respiratory impairment).
“-“ Denotes prediction interval was not able to be estimated.
TB, tuberculosis; HIV, human immunodeficiency virus; DS-TB, drug susceptible tuberculosis; MDR-TB, multidrug-resistant tuberculosis; FEV1, forced vital capacity in 1 second; FVC, forced vital capacity; %pred., percentage of predicted value; L, litres; CI, confidence interval.